Literature DB >> 25542574

Development and validation of a rapid turboflow LC-MS/MS method for the quantification of LSD and 2-oxo-3-hydroxy LSD in serum and urine samples of emergency toxicological cases.

Patrick C Dolder1, Matthias E Liechti, Katharina M Rentsch.   

Abstract

Lysergic acid diethylamide (LSD) is a widely used recreational drug. The aim of the present study is to develop a quantitative turboflow LC-MS/MS method that can be used for rapid quantification of LSD and its main metabolite 2-oxo-3-hydroxy LSD (O-H-LSD) in serum and urine in emergency toxicological cases without time-consuming extraction steps. The method was developed on an ion-trap LC-MS/MS instrument coupled to a turbulent-flow extraction system. The validation data showed no significant matrix effects and no ion suppression has been observed in serum and urine. Mean intraday accuracy and precision for LSD were 101 and 6.84%, in urine samples and 97.40 and 5.89% in serum, respectively. For O-H-LSD, the respective values were 97.50 and 4.99% in urine and 107 and 4.70% in serum. Mean interday accuracy and precision for LSD were 100 and 8.26% in urine and 101 and 6.56% in serum, respectively. For O-H-LSD, the respective values were 101 and 8.11% in urine and 99.8 and 8.35% in serum, respectively. The lower limit of quantification for LSD was determined to be 0.1 ng/ml. LSD concentrations in serum were expected to be up to 8 ng/ml. 2-Oxo-3-hydroxy LSD concentrations in urine up to 250 ng/ml. The new method was accurate and precise in the range of expected serum and urine concentrations in patients with a suspected LSD intoxication. Until now, the method has been applied in five cases with suspected LSD intoxication where the intake of the drug has been verified four times with LSD concentrations in serum in the range of 1.80-14.70 ng/ml and once with a LSD concentration of 1.25 ng/ml in urine. In serum of two patients, the O-H-LSD concentration was determined to be 0.99 and 0.45 ng/ml. In the urine of a third patient, the O-H-LSD concentration was 9.70 ng/ml.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25542574     DOI: 10.1007/s00216-014-8388-1

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  11 in total

1.  Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects.

Authors:  Friederike Holze; Urs Duthaler; Patrick Vizeli; Felix Müller; Stefan Borgwardt; Matthias E Liechti
Journal:  Br J Clin Pharmacol       Date:  2019-04-29       Impact factor: 4.335

2.  Development and validation of an LC-MS/MS method to quantify lysergic acid diethylamide (LSD), iso-LSD, 2-oxo-3-hydroxy-LSD, and nor-LSD and identify novel metabolites in plasma samples in a controlled clinical trial.

Authors:  Patrick C Dolder; Matthias E Liechti; Katharina M Rentsch
Journal:  J Clin Lab Anal       Date:  2017-05-26       Impact factor: 2.352

3.  Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers.

Authors:  Anya K Bershad; Scott T Schepers; Michael P Bremmer; Royce Lee; Harriet de Wit
Journal:  Biol Psychiatry       Date:  2019-06-03       Impact factor: 13.382

4.  Different Roles of Beclin1 in the Interaction Between Glia and Neurons after Exposure to Morphine and the HIV- Trans-Activator of Transcription (Tat) Protein.

Authors:  Jessica Lapierre; Mohan K M Karuppan; Marissa Perry; Myosotys Rodriguez; Nazira El-Hage
Journal:  J Neuroimmune Pharmacol       Date:  2021-11-05       Impact factor: 7.285

5.  LSD Acutely Impairs Fear Recognition and Enhances Emotional Empathy and Sociality.

Authors:  Patrick C Dolder; Yasmin Schmid; Felix Müller; Stefan Borgwardt; Matthias E Liechti
Journal:  Neuropsychopharmacology       Date:  2016-06-01       Impact factor: 7.853

6.  Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans.

Authors:  Patrick C Dolder; Yasmin Schmid; Manuel Haschke; Katharina M Rentsch; Matthias E Liechti
Journal:  Int J Neuropsychopharmacol       Date:  2015-06-24       Impact factor: 5.176

7.  Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects.

Authors:  Patrick C Dolder; Yasmin Schmid; Andrea E Steuer; Thomas Kraemer; Katharina M Rentsch; Felix Hammann; Matthias E Liechti
Journal:  Clin Pharmacokinet       Date:  2017-10       Impact factor: 6.447

8.  Alterations of consciousness and mystical-type experiences after acute LSD in humans.

Authors:  Matthias E Liechti; Patrick C Dolder; Yasmin Schmid
Journal:  Psychopharmacology (Berl)       Date:  2016-10-07       Impact factor: 4.530

9.  A Single Dose of LSD Does Not Alter Gene Expression of the Serotonin 2A Receptor Gene (HTR2A) or Early Growth Response Genes (EGR1-3) in Healthy Subjects.

Authors:  Patrick C Dolder; Edna Grünblatt; Felix Müller; Stefan J Borgwardt; Matthias E Liechti
Journal:  Front Pharmacol       Date:  2017-06-28       Impact factor: 5.810

Review 10.  Modern Clinical Research on LSD.

Authors:  Matthias E Liechti
Journal:  Neuropsychopharmacology       Date:  2017-04-27       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.